Form 4: Halozyme Therapeutics SVP, Chief Legal Officer Reports Stock Unit Transactions
SEC Form 4
Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, reports the acquisition and disposal of performance stock units (PSUs) based on performance measurements ending December 31, 2024.
Summary
- On February 12, 2025, Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, filed a Form 4.
- The filing reports transactions involving Performance Stock Units (PSUs).
- These PSUs were awarded on February 16, 2022, February 16, 2023, and February 23, 2024, with a performance measurement period ending December 31, 2024.
- The transactions reflect the determination of the number of stock units that became eligible to vest based on performance for the specified period.
- The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock unit transactions, indicating a neutral sentiment.
Future Outlook
The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
Industry Context
This filing is a routine disclosure related to executive compensation and stock-based awards, common in publicly traded companies. It provides transparency into the equity holdings and transactions of company insiders.
Stakeholder Impact
- Shareholders are informed about the equity-based compensation of a key executive.
- Employees may be interested in the vesting terms of performance stock units.
Key Dates
| Date | Description |
|---|---|
| 02/16/2022 | Grant date of performance-based vesting stock units (PSUs) with performance measurement period ending December 31, 2024 (6,050 units). |
| 02/16/2023 | Grant date of performance-based vesting stock units (PSUs) with performance measurement period ending December 31, 2024 (4,698 units). |
| 02/23/2024 | Grant date of performance-based vesting stock units (PSUs) with performance measurement period ending December 31, 2024 (7,269 and 30,050 units). |
| 12/31/2024 | Performance measurement period end date for all PSUs mentioned in the filing. |
| 02/12/2025 | Date of the transactions reported in the Form 4. |
| 02/14/2025 | Date of signature of the report. |
Keywords
Form 4, Halozyme Therapeutics, Performance Stock Units, PSUs, Beneficial Ownership, SVP, Chief Legal Officer, Stock Units, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.